| Name | Title | Contact Details |
|---|---|---|
Pete Coman |
Chief Technology Officer | Profile |
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea`s lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families.
LamdaGen Corp is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Myriad RBM is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zymo Research Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Ginkgo Bioworks we are expanding the role of biology in our world.Nature`s biodiversity holds answers to challenges in health, energy, food, materials, and more. Organism Engineers at Ginkgo learn from Nature to develop new organisms that replace technology with biology.